查詢結果分析
相關文獻
- Evaluation of Overexpressed Cannabinoid 1 Receptor in Liver Fibrosis Tissues via Detecting CB1R Antagonist, AM251, by MALDI-TOF MS in Vitro
- 基質輔助雷射脫附游離--飛行時間質譜技術及其應用
- 中醫藥抗肝纖維化研究的現狀和展望
- 中醫學辨證論治與肝纖維化動物模型的選擇
- 活血化瘀方藥抗大鼠肝纖維化的形態學和組織化學定量研究
- 中藥2號方抗肝纖維化的形態學和血清學實驗研究
- 質譜在環境污染物檢測上的應用
- 酒精性肝纖維化動物模型的建立
- 清熱利濕方藥抗肝纖維化的形態學和免疫組織化學定量研究
- 中醫藥抗肝纖維化的研究進展
頁籤選單縮合
題名 | Evaluation of Overexpressed Cannabinoid 1 Receptor in Liver Fibrosis Tissues via Detecting CB1R Antagonist, AM251, by MALDI-TOF MS in Vitro=質譜技術體外測定AM251驗證類大麻受體大量表現於肝纖維化組織中 |
---|---|
作者 | 程俊嘉; 何愛生; 羅彩月; 張榮善; 張甄; 張君照; | 書刊名 | 臺灣消化醫學雜誌 |
卷期 | 30:2 2013.06[民102.06] |
頁次 | 頁199-206 |
分類號 | 415.53 |
關鍵詞 | 肝纖維化; 類大麻受體; 質譜技術; Liver fibrosis; AM251; Cannabinoid 1 receptor; CB1R; Matrix assisted laser desorption ionization-time of flight mass spectrometer; MALDI-TOF MS; |
語文 | 英文(English) |
中文摘要 | 背景:肝纖維化會導致肝硬化及肝癌之發生,故有效偵測肝纖維化將預防肝疾病之惡化, 而可靠組織蛋白生物標記或許可用來設計成非侵入式的診斷方式以輔助臨床肝穿刺之不足,目前許多報導指出類大麻受體(cannabinoid 1 receptor, CB1R) 與肝纖維化具有關聯,因此也許可偵測類大麻受體以區分肝纖維化分級,本篇便利用質譜技術偵測類大麻受體拮抗劑AM251 以驗證類大麻受體於肝纖維化組織中之表現,並評估類大麻受體當作肝纖維化專一性蛋白生物標記之可行性。方法:大鼠以0.04% thioacetamide 加入飲用水中去誘導肝纖維化之生成,並利用hematoxylin andeosin (H&E) 染色區分肝纖維化分級(F0-F4),免疫組織化學染色法用以偵測類大麻受體之表現,而螢光顯微鏡用以觀察類大麻受體螢光拮抗劑tocriflour 1117 (T1117) 與肝纖維化組織之結合力,最後以質譜定性分析技術測定類大麻受體拮抗劑AM251 與肝纖維化之結合表現,用以驗證類大麻受體當作肝纖維化蛋白生物標記。結果:本研究發現類大麻受體大量表現於肝纖維化組織中,並與肝纖維化分級具有正相關,T1117 結合試驗證實AM251 專一性類大麻受體結合,而且質譜定性分析指出藉由分析AM251 可用以偵測肝纖維化並區分F0 到F4 (p < 0.05),同時驗證類大麻受體是肝纖維化專一性蛋白生物標記。結論:本研究的結果證實類大麻受體是肝纖維化專一性生物標記,並暗示體外偵測類大麻受體拮抗劑可幫助區分肝纖維化分級,我們建議AM251 可用以當作肝纖維化診斷標靶,用質譜偵測或標幟放射性同位素以開發臨床實用之肝纖維化診斷套組。 |
英文摘要 | Background: Liver fibrosis leads to liver cirrhosis and even cancer progressively, but can be preventedthrough early detection. A reliable tissue biomarker is desirable in order to design a non-invasive diagnosing tool tocomplement invasive liver biopsy. Presently many studies have reported that the cannabinoid 1 receptor (CB1R) isassociated with liver fibrosis, and therefore it is possible to measure the expression of CB1R for detecting the stagesof liver fibrosis. The aim of this study was to measure the protein expression of CB1R via detecting its antagonist,AM251, utilizing biomedical techniques and matrix assisted laser desorption ionization-time of flight (MALDI-TOF)mass spectrometer in vitro.Methods: The rats were treated with/without 0.04% thioacetamide to induce each stage of liver fibrosis(F0-F4) which was determined by hematoxylin and eosin (H&E) staining according to METAVIR Classification.Immunohistochemistry was used to detect the expression and position of CB1R. Fluorescent microscopy was used toobserve the binding capacity of tocriflour 1117 (T1117), a fluorescent analogue of AM251, to CB1R. MALDI-TOFMS was used to measure the amount of AM251 after incubating with liver fibrosis tissue sections.Results: CB1R overexpressed in the liver fibrosis tissues and increased from F0 to F4 stage. T1117 bindingassay showed that AM251 could interact with CB1R specifically. Moreover, the quantification analysis of MALDITOFMS indicated that AM251 could present the amount of CB1R in each stage of liver fibrosis with increase fromF0 to F4 (p<0.05).Conclusion: We showed that CB1R overexpressed in liver fibrosis tissues as a reliable biomarker. The dataimply that in vitro measurement of CB1R antagonist, AM251, may help distinguish the stages of liver fibrosis.Furthermore, we suggest that AM251 may be used as a detecting ligand and applied in nuclear imaging techniquefor diagnosing liver fibrosis. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。